Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

SEC Filing Summary: Ekso Bionics Holdings, Inc.

Business Context and Reporting Period

This Form 8-K was filed by Ekso Bionics Holdings, Inc. on February 7, 2021. The registrant is incorporated in Nevada and trades on the Nasdaq Capital Market under the symbol "EKSO." The report addresses a specific corporate governance event rather than periodic financial results.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a personnel change and does not contain financial statements or performance metrics.

Material Changes

The material change reported is the resignation of Ted Wang, Ph.D., from the Board of Directors and all associated committees. The resignation is effective February 28, 2021.

Management Commentary and Risks

Management stated that Dr. Wang's resignation is due to increased time commitments arising from new business opportunities. The filing explicitly confirms that the departure is not the result of any disagreement with the Company regarding its operations, policies, or practices. No other risks, contingencies, or unusual items are disclosed in this document.

Key Facts for Investor Verification

  • Dr. Ted Wang's resignation from the Board is effective February 28, 2021.
  • The departure is voluntary and unrelated to any internal disputes.
  • The Company is classified as an emerging growth company.
  • Jack Peurach, Chief Executive Officer, signed the report on February 8, 2021.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.